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Areas covered in this review: We focus our attention on data on the efficacy
of currently available and emerging drugs for the management of cancer
treatment induced bone loss (CTIBL) found in a PubMed research from 1997
till today.
Importance of the field: One of the most common and severe safety issues of
the antihormonal therapy in both sexes is the CTIBL and the related fragility
fractures. In postmenopausal women with estrogenic receptor positive breast
cancer, the third-generation aromatase inhibitors (AIs) are the standard
therapy. Observational retrospective studies have found that AIs treated
patients had a high rate of bone loss and fracture risk (RR 1.3). Also in
men with prostate cancer receiving androgen deprivation therapy, the
increase in bone turnover and the consequent bone loss are very rapid and
sustained significantly increasing the fracture risk.
What the reader will gain: The aim of our review is to provide the
current evidences for the management of bone loss and fracture risk in
this subpopulation.
Take home message: The very high rate of bone loss and the high incidence
of fractures indicate that cancer patients at risk of CTIBL need to be carefully
monitored and stratified for fracture risk. Although there is a strong
evidence of efficacy in prevention of bone loss and reduction of fracture
risk for many drugs approved for postmenopausal osteoporosis (PMO) and
male osteoporosis, for CTIBL there are actually no drugs approved for
this indication.
Keywords: androgen deprivation therapy, aromatase inhibitors, bisphosphonates,
cancer treatment induced bone loss, denosumab
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1. Background
Many patients with breast and prostate cancers are treated with antihormonal
therapy in order to inhibit disease progression and prevent disease recurrence. Ovarian
failure develops within 1 year of therapy in 63 – 96% of premenopausal women with
breast cancer who receive post-operative adjuvant chemotherapy mainly with cyclo-
phosphamide, methotrexate and 5-fluorouracil [1,2]. Hormone-ablative therapies and
chemotherapy-induced menopause are used to cause a marked and rapid fall of
circulating and tissutal sex hormones, particularly useful in hormone-dependent cancer.
As a result of earlier diagnosis, more efficacious treatments and longer survival, more
patients than in the past are receiving long-term hormonal treatment for breast and
prostate cancers. The increasing breast and prostate cancer survivor population,
estimated at slightly > 2 million women in the US in 2005 and > 500,000 men a
year may be at risk for long-term effects of these beneficial treatments [3-5]. One of the
most common and severe safety issues of the antihormonal therapy in both sexes is the
so-called cancer treatment induced bone loss (CTIBL) and the related fragility fractures.
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In the evaluation of the impact of the hormonal adjuvant
therapies on bone health in cancer patients we should take
into account that most patients with breast and prostate
cancers are > 65 years old and that the risk of osteoporotic
fractures is partially independent of cancer therapies. About
70% of prostate cancer patients have osteopenia or oste-
porosis detected by DEXA before starting antiandrogen ther-
apy [4,6,7] and about 20 – 60% of them have a high prevalence
of 25(OH)D levels deficiency (< 20 ng/ml) [8] with a signifi-
cantly increased risk of fragility fractures during the 12 months
before androgen deprivation therapy (ADT) [9]. Breast cancer
patients have a high prevalence of secondary causes of osteo-
porosis such as low levels of 25(OH)D, idiopathic hypercal-
ciuria and hyperparathyroidism, excluding aromatase
inhibitors (AIs), gonadotropin-releasing hormone (GnRH)
and chemotherapy [10]. The hypogonadal state resulting
from hormonal adjuvant therapy is more severe and complete
than that found in early or late menopause and in aging
men [11]. Therefore, the secondary increase of bone turnover,
with a negative unbalance between bone formation and bone
resorption, induces an impressive high rate of bone loss,
exceeding about fivefold that seen in postmenopausal women
or in aging men [12]. Thus, accelerated bone loss from CTIBL
will be especially concerning in this setting of cancer patients.
In women at the time of the first diagnosis of breast cancer,
the incidence of vertebral fractures over the next 3 years was
nearly fivefold higher than in the normal population. The risk
was > 20-fold greater in women with recurrent breast cancer
but no evidence of skeletal metastasis [13]. Interestingly, the
prevalence of vertebral fractures was similar in women with
breast cancer at the time of the first diagnosis to that in an age-
matched sample of the general population [13]. More recently,
the prospective analysis on 90,000 postmenopausal women
participating to the WHI-OS study confirmed that breast
cancer survivors experienced a high yearly rate of any type of
fracture with an increase of 31% in fracture risk compared to
control subjects [14].
In premenopausal women, chemotherapy-induced meno-
pause, either temporary or permanent, is associated with a
rapid bone loss (2 – 4%) within 1 year of initiation of adjuvant
chemotherapy for breast cancer [15,16]. In women with per-
sistent menopause after chemotherapy, clinically significant
bone loss continued during the following 2 – 5 years [17].
Recently, premenopausal women with endocrine-responsive
breast cancer were randomly assigned to receive endocrine
therapy alone (GnRH and tamoxifen or letrozole) or endo-
crine therapy plus upfront zoledronic acid [18,19]. The women
with hormonal therapy alone during the 3 years treatment
course had a very impressive bone loss both at the lumbar
spine (-11.3%) and at the hip (-7.3%) with a mean rate of
bone loss of about 3% a year [18,19].
In postmenopausal women with breast cancer and estro-
genic receptor positive, the third-generation AIs (anastrozole,
letrozole and exemestane) have generally replaced tamoxifen
alone because of their better effectiveness in preventing disease
recurrence in estrogenic receptor positive early breast can-
cer [20]. All of these third-generation AIs inhibit aromatase
activity by > 98% [20,21]. In the postmenopausal state, unlike
tamoxifen, AIs specifically block the conversion of mainly
adrenal androgens to estrogens at tissue level, abolishing the
protective effects of residual estrogens [21,22]. Moreover, AIs
have a favourable side effect profile compared to tamoxifen but
because of the well-known relationship between estrogens
levels and fracture risk, a negative impact on bone metabolism
would be expected. Observational retrospective studies have
found that AI treated patients had a higher prevalence of bone
loss (8.7%) than not treated patients (7.1%) and a higher
prevalence of bone fracture (13.5 vs 10.3%) [23]. The treat-
ment with AI seems to increase 2.5-fold the probability to
have a fracture in breast cancer women with respect to
tamoxifen [24]. Clinical evidences from randomized controlled
trials (RCTs) have shown that AIs are associated with bone
loss and increased fracture rates. The rate of bone loss induced
by AIs at the lumbar spine and hip ranges from 1.7% to as
much as 5.8% a year with an average rate of bone loss of 2% a
year [25-31] which significantly exceeds the gradual 1%
observed in PMO women [29,32-34]. The high rate of bone
loss is maintained through a rapid and sustained increase of
bone turnover during AI treatment, with serum levels of
N-terminal propeptide of collagen type 1 (P1NP), N- and
C-terminal crosslinking telopeptides of type I collagen (NTX
and CTX, respectively) that significantly exceed the levels
observed in control group from 20 to 45% [25-31,35-38]. The
increases in annual fracture rate are similar for all three AIs [39].
In the Anastrazole, Tamoxifen, Alone or in Combination
trial a 43% increase was reported in fracture rate for women
receiving anastrazole comparedwith tamoxifen therapy (annual
fracture rate 2.9% for anastrazole vs 1.9% for tamoxifen).
Similar increases in fracture rate versus tamoxifen were reported
with letrozole (48%) and exemestane (40%) [18,26,39-44].
Androgen deprivation therapy (ADT) is commonly used in
advanced prostate cancer and is increasingly used before the
development of bone metastasis, particularly as additional
therapy to radiation or prostatectomy in high-risk or locally
advanced disease [45].
In aging men, the decrease of sex steroids results in a gradual
bone loss of 0.5 – 1% a year [46]. In men with prostate cancer
receiving ADT, as in AI treated women, the increase in bone
turnover and the consequent bone loss are very rapid and
sustained during hormonal adjuvant therapy. Prospective
longitudinal studies have reported decreases in bone mineral
density (BMD) after 1 year of ADT ranging from no signif-
icant decrease to -4.8% at the spine and to -3.8% at the total
hip [47-59]. In RCTs studing the preventive role of bis-
phosphonates (BPs), the annual rates of bone loss ranging
from no significant changes to 5.7% at the spine and 2.8% at
the hip are confirmed [45]. Significant changes are already
detectable at 6 months after the beginning of ADT in non-
metastatic prostate cancer and are characterized by an increase
in bone markers [58,60]. The rate of bone loss per year of
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treatment was irrespective to the type of ADT (GnRH agonist
alone or plus antiandrogen, GnRH agonist plus antiandrogen
and orchiectomy, intermittent ADT plus antiandrogen) rang-
ing from -1.4 to -4.6% [46]. Other cross-sectional studies
confirm progressive reduction in BMD with increasing dura-
tion of ADT [61-63]. However, fractures remain the most
significant clinical problem related to CTIBL induced by
ADT, influencing, as independent predictor, the survival of
these patients [64].
The fracture rate due to ADT in prostate cancer patients has
not yet been established with prospective studies. However,
several retrospective studies provide significant evidences of
increased fracture risk [45]. An analysis of 15,716 men with
fractures and 47,149 matched controls in a nationalwide
population-based case control study found an increased frac-
ture risk for GnRH agonist treated patients, with or without
antiandrogen therapy (odds ratio (OR) 1.7; 95% CI,
1.2 – 2.5) or orchiectomy (OR 1.7; 95% CI, 1.2 – 2.4)
adjusting values for prior fractures, age and prostate cancer [65].
A pharmaceutical claims-based analysis of 12,120 men with
prostate cancer reported a risk fracture rate of 7.91 versus 6.55
per 100 person/year at risk in GnRH group and ADT naive
control, respectively [66]. A review of the records of 50,613
men having received a diagnosis of prostate cancer during a
5-year period showed that 19.4% of those who received ADT
had fractures, as compared with the 12.6% of those who did
not receive ADT [9,67]. Furthermore, a significant relation
between the number of received doses of GnRH agonist
during 1 year and the subsequent fracture risk was found,
the treatment duration independently predicting fracture risk.
A Medicare claims analysis of 10,617 men reported for men
receiving GnRH agonists compared with controls a fracture
risk of 7.88 versus 6.51 per 100 person/year at risk, respec-
tively, with a significant relationship with the duration of
ADT treatment [68].
However, it should be noted that the real rate of fracture
in CTIBL could be underestimated because in RCTs and in
epidemiological studies only clinical fractures are captured
not taking into account that about 50% of the fragility
fractures are morphometric vertebral fractures that are
completely asymptomatic and are assessed only with a pre-
planned sequential spine X-rays. Actually, there are no RCTs
planned to measure morphometric fractures of the spine.
Furthermore, the use of BMD T-score as surrogate parameter
of fracture risk in CTIBL could induce an additional under-
estimation of the real risk of fragility. BMD T-score thresh-
old for the diagnosis of osteoporosis is validated by the
WHO only for PMO osteoporosis and not for other con-
ditions. This is not totally reassuring [28,69]. The high bone
turnover and the high rate of bone loss, characterizing the
CTIBL, predict fracture risk independently from BMD,
probably reflecting bone microarchitecture deterioration [70].
It is likely that cancer patients with CTIBL have a
different BMD fracture threshold if compared to other types
of osteoporosis.
2. Medical need
There are strong evidences that both in breast and prostate
cancers, adjuvant hormonal therapy increasing survival
and inducing bone loss impacts significantly on bone health
of survivors increasing their susceptibility to fragility fractures.
The very high rate of bone loss and the high incidence of
fractures persisting for the duration of the endocrine adjuvant
therapy and beyond indicate that cancer patients at risk of
CTIBL need to be carefully monitored, correctly stratified for
fracture risk and properly treated.
Recently, expert panels and position papers have suggested
a new approach to assess fracture risk and to establish
the treatment threshold, which integrates better levels of
BMD (T-score lower of -1 DS) with independent predictors
of fracture (age, previous fractures, familial history of frac-
tures, corticosteroids therapy), similar to what has happened
to the fracture risk assessment in postmenopausal osteopo-
rosis [71-74]. Therefore, the last version of the ASCO guide-
lines (2003) for women with breast cancer and the expert
panels for prostate cancer men [75,76] on the basis of recent
evidences should not be followed because they potentially
exclude a portion of patients with CTIBL at risk of fracture
from therapeutic attention.
Although all guidelines and expert panels regarding
CTIBL indicate the necessity to prevent and treat CTIBL,
currently there are no approved therapies. All guidelines and
position papers suggest the use of inhibitors of bone
resorption, mainly bisphosphonates (BPs). BPs are currently
proposed because of their effect on BMD and their efficacy
in reducing fracture risk. They are the gold standard in
PMO, glucocorticoid-induced and male osteoporosis. In
addition, consistent data suggest that BPs can largely pre-
vent CTIBL as indicated by BMD measurements [45].
However, several questions remain regarding which therapy
may be more suitable in CTIBL setting, that is, BPs or
raloxifene, or other new drugs approved for PMO and male
osteoporosis. Actually, the evidences of risk fracture reduc-
tion in CTIBL setting with BPs treatment are surprisingly
lacking and only a few data with new antiresorptive ther-
apies, that is, denosumab, have been recently published [77].
Furthermore, available guidelines on the use of BPs in
CTIBL do not indicate which BP is the most appropriate,
which route of administration (oral or intravenous) is more
convenient, which is the right dose and how long BP
therapy should be continued [71,72]. However, the strongest
evidences in treatment of CTIBL in breast cancer are
obtained with zoledronic acid 4 mg every 6 months that
is about twofold the dose approved for PMO (zoledronic
acid 5 mg yearly) [45,78].
In conclusion, actually the growing evidences that indicate
the need to manage the long-term complications arising from
endocrine adjuvant therapies in cancer patients conflict with
the scarce evidences of efficacy on fracture risk of the current
treatments, mainly BPs.
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3. Existing treatments
Regarding the pathophysiologic and molecular pathways of
bone loss in postmenopausal osteoporosis and CTIBL, there
are apparently no reasons to consider that these two conditions
are different. Therefore, it should be a logical consequence that
the same drugs used in PMO would also be useful in CTIBL.
The currently used drugs for PMO and aging men act in
one of these three ways: as inhibitors of bone resorption
(antiresorptive drugs); as stimulators of bone formation (ana-
bolic drugs) and by a combination of both mechanisms, that
is, dual-acting agents.
The standard treatment for PMO is the inhibition of bone
resorption with BPs, selective estrogen receptor modulators
(SERMs) and estrogens [79,80]. BPs actually are the first-line
therapy in PMO for their safety and efficacy profile.
The anabolic therapy with teriparatide (1 – 34) or para-
thormone (1 – 84) has recently proved to be effective in severe
osteoporosis with an impressive increase in bone mass in a
relative short treatment time [81].
Finally, strontium ranelate has been recently introduced in
PMO therapy for the proven efficacy in preventing both
vertebral and non-vertebral fractures [82]. Its mechanism of
action is not fully explained even if there are sparse evidences
of a mixture of antiresorptive and anabolic effect (dual-acting
agent) [83].
Although teriparatide, parathormone and strontium rane-
late are not officially contraindicated in cancer patients, there
are some concerns in their use in CTIBL regarding their
mechanism of action. In fact, recent data about the role of
bone turnover in homing of cancer cells into the bone raise
questions about the safety profile of these drugs in this setting
of patients. Moreover, the molecular similarity of teriparatide
and parathormone 1 – 84 with parathyroid hormone-related
protein (PTHrp) could not exclude potential direct effects on
cancer cells via the interaction with the parathyroid hormone
(PTH) receptor, as proven in animal studies [84].
These concepts explain why only the inhibitors of bone
resorption are studied and developed in CTIBL.
3.1 Therapeutic class review
3.1.1 Bisphosphonates in breast cancer treatment
induced bone loss
Several BPs are currently available for the treatment of age
related or menopausal osteoporosis, as well as treatment and
prevention of skeletal metastasis in solid tumours (Table 1).
Although not approved for bone loss associated with cancer
treatments, BPs have shown significant benefits in clinical
trials. The magnitude of prevention of BMD losses and even
some increases in BMD achieved with BPs suggest that a
proactive approach with this drug class may decrease fracture
risk among patients with breast cancer [85].
We will, therefore, examine the most important studies for
each type of BP in the setting of breast and prostate CTIBL
(Tables 2 and 3).
3.1.1.1 Clodronate
Clodronate (both oral and intravenous (i.v.)) has been
investigated in CTIBL. Saarto et al. [86] conducted a 3-years
RCT with 1600 mg of oral clodronate daily or placebo of
121 postmenopausal breast cancer women without skeletal
metastasis during adjuvant treatment with SERMs demon-
strating that oral clodronate significantly increased BMD at
lumbar spine (+2.9%) and femoral neck (+3.7%) at 2 years.
Two studies have also been performed in premenopausal
women with chemotherapy-induced ovarian failure. In
the first one [15], 2-years of oral clodronate treatment
reduced the mean BMD loss at the lumbar spine from -5.9
to -2% and at the femoral neck from -2.2% to +0.9%
(p = 0.0005 and 0.017, respectively). In the second study,
there was no difference in bone loss of lumbar spine BMD
between seven cycles of 1500 mg of clodronate i.v. for 1 year
or placebo [87].
3.1.1.2 Risedronate
Delmas et al. [88] performed a randomized, placebo-controlled
study of 53 women with breast cancer and artificially induced
menopause, 36 of them were taking tamoxifen 20 mg/day.
They have evidenced that oral risedronate therapy (8 cycles
oral risedronate 30 mg/day or placebo daily for 2 weeks
followed by 10 weeks of no drug, 12 weeks per cycle) in
premenopausal women with chemotherapy or radiotherapy-
induced ovarian failure after breast cancer surgery reduced
mean BMD loss at the lumbar spine by 2.5% (p = 0.041), at
the trochanter by 3.1% (0.002) and at the femoral neck by
2.6% (p = 0.029) compared with placebo. Risedronate has
also been investigated in postmenopausal women during
anastrozole therapy for early breast cancer (SABRE
study) [89,90]. The primary end point of the study was lumbar
spine BMD change from baseline at 12 months. At 1 year,
BMD increased by 1.7 and 1.3% at lumbar spine and total
hip, respectively; however, in the placebo group, BMD
decreased by 0.4 and 0.1%, respectively. Greenspan
et al. [91] confirmed in a cohort of 87 postmenopausal women
with breast cancer with or without AI therapy randomly
assigned to once-weekly risedronate 35 mg or placebo for
24 months that oral risedronate was beneficial for spine and
hip BMD (difference of 1.6% at the spine and 2.5% at the
hip, p < 0.05) and reduced bone turnover.
On the other hand, the group of Hines et al. [92] evidenced in
a randomized placebo-controlled study in 216 premenopausal
women undergoing adjuvant chemotherapy for breast cancer
that risedronate 35 mg/weekly did not prevent bone loss.
3.1.1.3 Alendronate
Two studies have evaluated the effects of oral alendronate
on BMD in postmenopausal women with breast cancer.
Improvements were noted in spine and hip BMD but
the number of patients was too small to perform statis-
tical analyses demostrating a significant difference from
placebo [93].
Emerging drugs for the management of cancer treatment induced bone loss
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3.1.1.4 Ibandronate
Monthly oral ibandronate (150mg) has also been evaluated for
preventing bone loss in a randomized, placebo-controlled study
of 131 postmenopausal women with early breast cancer receiv-
ing anastrozole 1 mg/day. After 2 years, osteopenic patients
treated with ibandronate gained +2.98 and +0.60% at the
lumbar spine and hip, respectively. Patients treated with
placebo, however, lost -3.22% at the lumbar spine and
-3.9% at the hip (p = 0.01 at both sites). Urinary n-telopep-
tides, serum c-telopeptide and serum bone-specific alkaline
phosphatase levels decreased in patients receiving ibandronate
of 30.9, 26.3 and 22.8%, respectively, at 12 months and
increased in those taking placebo (40.3, 34.9 and 37%,
respectively) [94].
3.1.1.5 Zoledronate
Recently, trials have examined the preventive role of the BPs
among PMO women receiving AIs. The largest of these
trials, the Zometa-Femara Adjuvant Synergy Trials
(Z-FAST, ZO-FAST), an open-label, multi-center, random-
ized study, evaluated i.v. zoledronic acid administered at a
dose of 4 mg every 6 months in 602 women receiving
adjuvant letrozole with baseline T-score > -2.0 DS. In one
treatment arm, zoledronic acid was initiated concurrently
with letrozole, whereas in the other arm treatment was delayed
until BMD loss. One-year results from the Z-FAST trial
showed an increase in mean lumbar spine BMD of 1.9%
from baseline in the upfront zoledronic acid arm compared
with a mean decrease of 2.4% with delayed administration
with an overall difference of 4.4% (p < 0.0001) [27]. A report
after 36 months of follow-up indicated that the absolute
difference in lumbar spine BMD between the arms increased
to 6.7% (p < 0.001), with more fractures in the delayed arm
versus the concurrent arm (6.3 vs 5.6%, respectively),
although the study was not powered to detect differences
in fracture [95]. One-year results from the ZO-FAST trial are
comparable, with an overall difference of 5.7% between the
study arms in favour of upfront administration [96]. Prelim-
inary findings after 24 months of follow-up continue to
demonstrate a significant difference in BMD in favour of
upfront zoledronic acid [97]. In the Austrian Breast and
Colorectal Study Group-12 (ABCSG-12), a well-known
randomized, open-label, Phase III, four-arm trial they have
compared tamoxifen and goserelin (a GnRH agonist) versus
anastrozole and goserelin both with or without zoledronic acid
for 3 years in 1803 premenopausal women with endocrine
responsive breast cancer. In all, 404 patients were prospectively
included in the bone substudy and randomly assigned to
Table 1. Currently available drugs for the treatment of cancer treatment induced bone loss.
Compound Company Indication Stage of
development
Mechanism of action
Alendronate Merck & Co. Osteoporosis Marketed Inhibition of farnesil pirophosphate
synthase in the mevalonate pathway
Risedronate Procter &
Gamble
Osteoporosis Marketed Inhibition of farnesil pirophosphate
synthase in the mevalonate pathway
Clodronate Abiogen Osteoporosis Marketed Induction of osteoclast apoptosis
Pamidronate Generics Bone metastases Marketed Inhibition of farnesil pirophosphate
synthase in the mevalonate pathway
Ibandronate Roche Osteoporosis Marketed Inhibition of farnesil pirophosphate
synthase in the mevalonate pathway
Zoledronate Novartis Osteoporosis, bone metastases Marketed Inhibition of farnesil pirophosphate
synthase in the mevalonate pathway
Lasofoxifene Pfizer Hormone replacement therapy,
menopausal symptoms, osteoporosis
Marketed Agonist/antagonist action on
estrogen receptor
Raloxifene Eli Lilly Osteoporosis, hormone replacement
therapy, breast cancer
Marketed Agonist/antagonist action on
estrogen receptor
Bazedoxifene Wyeth Menopausal disorders, osteoporosis Marketed Agonist/antagonist action on
estrogen receptor
Toremifene Orion Pharma Treatment of hormone receptor positive
breast cancer in postmenopausal women
Marketed Agonist/antagonist action on
estrogen receptor
Fulvestrant AstraZeneca Treatment of hormone receptor positive
metastatic breast cancer in
postmenopausal women
with disease progression
after antiestrogen therapy
Marketed Estrogen receptor antagonist
with no estrogen agonist effect
Pharmaprojects – Copyright to Citeline Drug Intelligence (an Informa business). Readers are referred to Pipeline (http://informa-pipeline.citeline.com) and Citeline
(http://informa.citeline.com).
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receive or not zoledronic acid 4 mg every 6 months. After
3 years of treatment, patients who received zoledronic acid
had stable BMD both at the lumbar spine and at the hip
versus a decrease of 11.3 and 7.3%, respectively, in the control
group [19].
3.1.2 Bisphosphonates in prostate cancer treatment
induced bone loss
3.1.2.1 Alendronate
Once weekly oral alendronate resulted to be effective in
reducing bone loss in 112 men with non-metastatic prostate
cancer receiving ADT. This randomized, double-blind,
placebo-controlled, partial crossover trial demonstrated that
inmen treated with alendronate 70mg/weekly BMD increased
over 1 year by 3.7% (p < 0.001) at the spine and by 1.6%
(p = 0.008) at the femoral neck. Men in the placebo group had
losses of 1.4% at the spine and 0.7% at the femoral neck. Bone
turnover statistically significantly decreased in the alendronate
group compared with placebo [98].
3.1.2.2 Risedronate
Ishizaka et al. evaluated 61 prostate cancer patients who
had received ADT for about 40 months and treated with
2.5 mg of risedronate daily for 6 months. BMD remained
stable in the femoral neck and radius during risedronate
therapy. In contrast, the BMD of the lumbar spine showed a
gain of 4.9 + 8.9%. Urinary N-telopeptide of type I collagen
decreased significantly after 3 months of treatment [99].
Moreover, Izumi et al. demonstrated in a prospective
observational study of 60 Japanese patients with prostate
cancer who were receiving ADT that oral administration
of risedronate is effective for the recovery of ADT-induced
bone loss [100].
3.1.2.3 Pamidronate
Diamond et al. conducted a double-blind, randomized,
placebo-controlled, crossover study. A single infusion of
pamidronate in 21 men receiving ADT for prostate cancer
resulted in a significant increase of 2% in femoral neck
BMD and of 7.8% in lumbar spine (assessed with QCT)
in a 1 year period [101]. Smith et al. conducted an open-
label study in which they randomly assigned 47 men with
prostate cancer and no evidence of bone metastases to receive
either leuproline (a GnRH agonist) alone or leuproline and
pamidronate (60 mg intravenously every 12 weeks). The
group treated with leuproline experienced a significant
Table 2. Bisphophonates in breast cancer treatment induced bone loss.
Study Drug BMD changes Time Bone turnover
markers changes
Saarto et al. 1997 [86] Clodronate 1600 mg/day LS + 2.9% vs placebo
FN + 3.7% vs placebo
2 years Not available
Saarto et al. 1997 [15] Clodronate 1600 mg/day LS + 3.9% vs placebo
FN + 3.1% vs placebo
2 years Not available
Vehmanen et al. 2004 [87] Clodronate 7 cycle of
1500 mg i.v. for 1 year
No significant change vs placebo 1 year Not available
Delmas et al. 1997 [88] Risedronate 30 mg/day
for 8 cycles
LS + 2.5% vs placebo
Hip + 3.1% vs placebo
FN + 2.6% vs placebo
2 years Not available
Eastell et al. 2007 [89] Risedronate 35 mg/weekly LS + 1.7% vs basal
FN + 1.3% vs basal
1 year Not available
Greenspan et al. 2008 [91] Risedronate 35 mg/weekly LS + 1.6% vs placebo
Hip + 2.5% vs placebo
2 years Not available
Hines et al. 2008 [92] Risedronate 35 mg/weekly Does not prevent bone loss vs placebo
Sawka et al. 2005 [93] Alendronate 70 mg/weekly No significant difference vs placebo
Lester et al. 2008 [94] Ibandronate 150 mg/month LS + 2.98% vs basal
Hip + 0.60% vs basal
2 years u-NTX -30.9%
s-CTX -26.3%
BALP -22.8%
vs basal
Brufsky et al. 2007 [27,95] Zoledronate 4 mg/6 months LS + 1.9% vs basal
LS + 6.7% vs no treatment
1 year
3 years
Not available
Not available
Bundred et al. 2008 [96] Zoledronate 4 mg/6 months LS + 5.7% vs no treatment 1 year Not available
Gnant M et al. 2008 [19] Zoledronate 4 mg/6 months Stable vs basal 3 years Not available
Pharmaprojects – Copyright to Citeline Drug Intelligence (an Informa business). Readers are referred to Pipeline (http://informa-pipeline.citeline.com) and Citeline
(http://informa.citeline.com).
BALP: Bone alkaline phosphatase; BMD: Bone mineral density; FN: Femoral neck; i.v.: Intravenous; LS: Lumbar spine; s-CTX: Serum c-telopeptide;
u-NTX: Urinary n-telopeptide.
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decrease in BMD at any site in a 48 week period of
time whether the mean BMD in the group treated with
pamidronate did not change significantly in the same time
period [102].
3.1.2.4 Zoledronate
Israeli et al. evaluated the efficacy of zoledronic acid in
preventing BMD loss and suppressing bone marker in patients
with locally advanced prostate cancer during ADT treating
200 patients randomly assigned them to receive either
zoledronic acid 4 mg every 3 months or placebo. At week
52, the least squares mean BMD percentage differences
were 6.7% for lumbar spine and 3.7% for total hip
(p < 0.0001 for both) [103]. Bhoopalam et al. investigated
the efficacy of zoledronic acid in 93 patients with prostate
cancer who were on ADT for 1 year in mean. They were
assigned to receive either zoledronic acid 4 mg every 3 months
for four treatments or i.v. placebo. They demonstrated
that zoledronic acid significantly improved lumbar spine
BMD of 5.95% versus placebo [104]. Zoledronic acid
administered at a dose of 4 mg every 3 months for 1 year
is the most commonly investigated BP in prostate cancer
with several RCTs reporting significantly increased BMD
ranging from 3.3 to 5.6% in the spine and 0.7 to 1.6%
in the total hip, regardless of whether the patients were
already receiving ADT [103,105-107] or starting ADT at study
enrolment [108,109].
Finally, we should discuss a little about the fact that BPs
dose-finding studies in CTIBL have not been performed.
Alendronate, risedronate and ibandronate in CTIBL have
been studied at doses with evidences of antifracture efficacy
in postmenopausal osteoporosis (PMO), glucocorticoid and
male osteoporosis, while in the majority of zoledronic acid
studies it has been used at a higher dose, almost double than
that approved for prevention of fractures in PMO and male
osteoporosis (5 mg/year). If the primary end point is the
prevention of bone loss, probably all the doses tested are
adequate but if the primary end point is the fracture risk
reduction we can only speculate that the doses used for PMO
and male osteoporosis can be adopted in CTIBL supposing
that CTIBL is biologically similar to PMO and male osteo-
porosis. In other words, we do not know which is the correct
dose for the fracture risk reduction in CTIBL.
3.1.3 Denosumab
Bone loss is mediated by osteoclasts, whose formation, func-
tion, and survival depend on receptor activator of NF-kB
ligand (RANKL). RANKL binds to its receptor RANK on
preosteoclasts and mature osteoclasts and activates and main-
tains osteoclast-mediated bone resorption [110-113]. Denosu-
mab is a fully human mAb that specifically inhibits RANKL,
and suppresses bone resorption [113]. The effects of denosumab
on BMD have been explored also in the setting of
CTIBL (Table 4).
Denosumab increased lumbar spine BMD versus placebo
(p < 0.05) in a 2 year randomized, placebo-controlled,
Phase III study of 252 patients with hormone receptor
positive, non-metastatic breast cancer and low bone mass
who were receiving adjuvant AI therapy. Denosumab treat-
ment was associated with statistically significant gains in
lumbar spine BMD compared with placebo. The treatment
effect of denosumab on BMD was maintained at 24 months.
The observed differences in BMD between denosumab and
placebo groups were statistically significant (p < 0.05) across
all skeletal sites and subgroups, except for radial BMD in
patients who had received steroidal AI [114].
Ellis et al. conducted a randomized, placebo-controlled
Phase III study over a 24 month period. They studied
252 patients during AI therapy who were randomly assigned
to receive placebo or subcutaneous denosumab 60 mg every
Table 3. Bisphosphonates in prostate cancer treatment induced bone loss.
Study Drug BMD changes Time Bone turnover
markers changes
Greenspan et al. 2007 [98] Alendronate 70 mg/week LS + 3.7% vs basal
FN + 1.6% vs basal
1 year Not available
Ishizaka et al. 2007 [99] Risedronate 2.5 mg/day LS + 4.9% vs basal
FN stable vs basal
6 months Not available
Diamond et al. 2001 [101] Pamidronate 60 mg i.v. only one infusion LS + 7.8% vs basal
FN + 2% vs basal
1 year Not available
Smith et al. 2001 [102] Pamidronate 60 mg i.v. every 12 weeks Stable vs basal 6 months Not available
Bhoopalam et al. 2009 [104] Zoledronate 4 mg every 3 months LS + 5.95% vs placebo 1 year Not available
Casey 2007 [108] Zoledronate 4 mg every 3 months LS + 3.3%
FN + 0.7%
1 year Not available
Smith et al. 2008 [109] Zoledronate 4 mg every 3 months LS + 5.6%
FN + 1.6%
1 year Not available
BMD: Bone mineral density; FN: Femoral neck; i.v.: Intravenous; LS: Lumbar spine.
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6 months. At 12 and 24 months, lumbar spine BMD
increased by 5.5 and 7.6%, respectively, in the denosumab
group versus placebo (p < 0.0001 at both time points).
Increases were observed as early as 1 month and were
not influenced by duration of AIs therapy. Markers of
bone remodeling were rapidly reduced with a median
percentage reduction from baseline of 91% compared
with 9% in the placebo group (p < 0.0001) [113]. Smith
et al. conducted a double-blind multi-center study in which
1468 patients with CTIBL in prostate cancer were randomly
assigned to receive either denosumab 60 mg subcutaneously
every 6 months or placebo. At 24 months, the denosumab
group experienced a gain of 5.6% in lumbar spine BMD
versus a decrease of 1% in the placebo group (p < 0.001)
and the difference between the two groups remained sig-
nificant through 36 months. Furthermore, patients who
received denosumab had a decreased incidence of new
vertebral fractures at 36 months (1.5 vs 3.9% with placebo;
p = 0.006) [77].
3.1.4 Selective estrogen receptor modulators
3.1.4.1 Raloxifene
Raloxifene resulted effective in preventing PMO bone loss over
a 3 year period in the MORE trial, a multi-center randomized,
blinded, placebo-controlled trial of 7705 women who were
randomized to receive 60 mg/day of raloxifene or placebo [115].
BMDgained after 3 years amounted to 2.1% at the spine and to
2.6% at the femur. Raloxifene reduced vertebral fractures over
3 years by 30 and 55% in women with and without prevalent
fractures, respectively [115-118]. The RUTH clinical trial, an
international multi-center, randomized, placebo-controlled
trial of 10,101 PMO women who were randomly assigned
to receive 60 mg/day of oral raloxifene or placebo, clearly
demonstrated the benefits of raloxifene in the prevention of
clinical fractures (33% reduction, p = 0.007) [119]. Despite the
strong rationale of using raloxifene in CTIBL, this compound
has not been tested in this setting.
3.2 Calcium and vitamin D supplementation
Calcium and vitamin D supplementations alone or combined
with antiresorptive therapies are critical in the management of
CTIBL. There are many arguments in favour of this.
First of all, the prevalence of vitaminD deficiency (25(OH)D
serum values below 30 ng/ml) or insufficiency (25(OH)D
below 20 ng/ml) are very common in almost every region of
the world studied, being particularly frequent in Southern
European countries [120]. Risk factors of vitamin D deficiency
include elderly, female sex, overweight, dark skin pigmenta-
tion, winter season and reduced sun exposition, dietary habits
and national policies of vitamin D fortification [120]. However,
it has been recently discovered that vitamin D deficiency is
pandemic, involving also children and healthy adults across
the world [121-123]. Therefore, it is not surprising that a high
proportion of patients with breast and prostate cancers have
low or very low plasma 25(OH)D levels [124,125], a condition
of particular concern in these patients, not only for their bone
health but also for the strong association with risk of cancer
incidence and mortality [126]. Recent meta-analysis evidenced
that vitamin D and calcium supplementation have chemo-
preventive effects against breast and prostate cancers, even if in
the latter the data are conflicting [126-129]. Secondary hyper-
parathyroidism is a direct consequence mainly of low 25(OH)
D levels rather than low calcium intake [128,130]. PTH eleva-
tion due to low 25(OH)D levels impairs the efficacy of the
antiresorbing agents, mainly BPs, by three to fivefold lower
BMD changes and by 1.5-fold increased risk of incidence of
fracture, in vitamin D insufficient as compared to vitamin D
repleted postmenopausal women [131]. However, in cancer
patients, secondary hyperparathyroidism is of particular con-
cern because PTH may have promotional activity on cancer
progression directly binding the PTHrp on cancer cells
(PTH1R) and indirectly enriching bone microenvironment
of cytokines and growth factors favoring the development and
progression of bone metastatic disease [132]. Therefore, optimal
vitamin D repletion seems to be necessary in cancer patients to
maximize the response to antiresorbing agents and probably to
obtain an anticancer effect. It is noteworthy that adequate
vitamin D doses (greater than 400 IU daily of cholecalciferol)
exert an additional antifracturative effect compared to anti-
resorptive agents, reducing the nonvertebral fractures by at
least 20% and the hip fractures by at least 18%, independently
of additional calcium supplementation [133]. Serum 25(OH)D
levels of 75 nmol/l (30 ng/ml) or higher can be considered
appropriate [134]. These levels provide optimal benefits beyond
Table 4. Other drugs tested in cancer treatment induced bone loss.
Study Drug BMD changes Time Bone turnover markers changes
Ellis et al. 2008 [113] Denosumab 60 mg/6 months LS + 5.5% vs placebo
LS + 7.6% vs placebo
1 year
2 years
-91% vs basal
Not available
Smith et al. 2009 [77] Denosumab 60 mg/6 months LS + 5.6% vs basal 2 years Not available
Smith et al. 2008 [157] Toremifene 80 mg/day LS + 2.3% vs placebo
FN + 1.5% vs placebo
Hip + 2% vs placebo
1 year Not available
BMD: Bone mineral density; FN: Femoral neck; LS: Lumbar spine.
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bone health (e.g., on hypertension, cardiovascular diseases,
falls, cancer, mortality) [134], and they could be influenced by
calcium intake, being somewhat lower with a high calcium
intake or higher with a very low calcium intake [135]. The
evidences from randomized trials suggest that the dose of
vitamin D supplementation needed to bring the large majority
of people to the optimal range of values of serum 25(OH)D is
far greater than that suggested by guidelines and administered
in almost all trials regarding BPs for the treatment of oste-
oporosis, CTIBL or bone metastases (about 400 – 600 IU
daily of cholecalciferol) [136]. Currently, a dose > 800 – 1000
IU daily, probably comprised between 1800 and 4000 IU per
day, is suggested [134]. Daily doses of 10,000 IU for 4 months
appear safe in breast cancer patients with bone metastases [137].
Among the available types of vitamin D, the inactive forms,
such as cholecalciferol, should be preferably used, as more safe,
cheap and usefully utilized by almost all tissues throughout
autocrine hydroxylation, rather than activated metabolites that
should be reserved to chronic renal failure [133].
3.3 Adherence and duration of therapy
About 50% of patients with postmenopausal osteoporosis fail
to comply or persist with anti-osteoporosis treatment regimens
within 1 year [138]. Poor compliance is associated with higher
fracture rates and increased morbidity, mortality and
costs [139,140]. Annually or biannually, i.v. BPs or subcutaneous
denosumab administered every 6 months could potentially
ameliorate this Achilles’ heel of osteoporosis treatment.
The optimal duration of treatment to prevent CTIBL could
be only speculative. There are data that indicate that the high
bone turnover, high rate of bone loss and the fracture risk
persist during endocrine adjuvant treatment with a significant
fall of fracture risk after the withdrawal in the subsequent
years [141].
On the other hand, BPs and denosumab maintaining the
bone turnover adequately suppressed induced a continued
improvement of BMD [113,142]. Therefore, the minimum
treatment period should cover the duration of endocrine
adjuvant treatment. At withdrawal of hormonal suppression,
the risk of fracture should be re-assessed and the antiresorbing
agents, without the emerging of new fracture risks, could be
withdrawn. Furthermore, there are consistent evidences that
the benefits of amino-BPs, mainly of the ones with higher
bone affinity such as zoledronic acid and alendronate, prob-
ably could not be limited to the treatment course, the
protective effects on BMD and fractures potentially extending
through some years after cessation [143]. The use of BPs
and denosumab in the future in CTIBL setting requires
further studies to more clearly define the most appropriate
timing and length of therapy as well as the long-term efficacy
and safety.
3.4 Safety/tolerability of antiresorbing agents
BPs are the most commonly prescribed medications for the
treatment of osteoporosis and actually represent the gold
standard for the treatment of bone metastases. Although
evidence supports a good safety profile for these agents,
numerous tolerability issues have been associated with their
use. Evaluating the safety and the tolerability of oral and
particularly i.v. BPs should be considered in that there are
consistent differences mainly in the schedules of administra-
tion between their use in bone metastatic, osteoporosis or
CTIBL setting, with annual cumulative doses about 12-fold
higher in the former setting. The major concerns for oral
amino-BPs are upper gastrointestinal (UGI) adverse events
including esophagitis, esophageal ulcer and erosive esophagitis
without apparently significant differences among BPs (alen-
dronate, ibandronate, risedronate) and placebo. In the ‘real
life’, the issue of UGI tolerability is strongly linked with the
correct following of the administration instructions. In
CTIBL setting, administration of zoledronic acid appears to
be well tolerated and the most frequent adverse event is the
influenza-like illness [25,144,145]. Its incidence ranges in about
10 – 50% of patients treated for the first time and can be
treated or prevented with acetominophene. Recently, it has
been found that a determinant of developing the acute phase
response are low pretreatment levels of 25(OH)D [146].
Osteonecrosis of the jaw (ONJ) has also been associated
with the use of amino-BPs. The ONJ associated with oral BPs
in osteoporosis is rare with an estimated prevalence of
0.7/100,000 patients/year [147]. One case of ONJ in the
zoledronic acid group and one patient in the placebo group
are reported in the pivotal trial for the prevention of osteo-
porotic fractures [148]. Out of a total of 2195 patients with
CTIBL treated with zoledronic acid [27,144,145], 6 cases of ONJ
have been reported and only 1 (< 0.005%) case has been
confirmed by the ONJ adjudication committee. Only three
patients had impaired renal function suspected to be related
to BP treatment [27,144,145]. Recently, a significantly higher
incidence of atrial fibrillation (1.3% in zoledronic group vs
0.5% in placebo group) has been reported associated with
the annual infusion of zoledronic acid for osteoporosis in a
pivotal trial [149] and afterwards suspected for oral BPs.
Actually, the heterogeneity and the paucity of the existing
data preclude any definitive conclusion on the exact nature
of the risk of this side effect [150]. In general, adverse events
due to oral and i.v. BPs used at low doses as in osteoporosis
and CTIBL setting are mild and easily manageable.
For denosumab (60 mg every 6 months), the most
common adverse effects in Phase III trials in prevention of
CTIBL in breast and prostate cancer patients were arthralgia,
pain at the extremities, back pain and fatigue with a similar
incidence in the placebo group [77,113]. In breast cancer
patients, serious AEs were reported in the 15% in the deno-
sumab group and in the 9% of the placebo group but none
was considered to be treatment related. Infections were
reported in the 2% of the denosumab group and in the
1% of the placebo group.
In prostate cancer patients, serious adverse events related to
infections were reported in the 5.9% of patients receiving
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denosumab and in the 4.6% of those receiving placebo. One
patient receiving denosumab had hypocalcemia whereas all
receiving placebo had it [77]. No cases of ONJ were reported in
both studies. A single case of ONJ has been recently reported
in a patient with prostate cancer and bone metastases partic-
ipating in a Phase III study with denosumab (120 mg/every
4 weeks) compared with zoledronic acid (4 mg/every 4 weeks).
He completed a course of chemotherapy with docetaxel
and prednisone and his current medication was LHRH,
stilboestrol and doxazosin [151].
4. Competitive environment
4.1 Selective estrogen receptor modulators
4.1.1 Bazedoxifene
Bazedoxifene is an indole-based estrogen receptor (ER) ligand
which exerts significant estrogenic and antiestrogenic activity
both in vitro and in vivo targeting any tissue that has ERs
(Table 5). Phase III studies of bazedoxifene, particularly a
3 year, randomized, double-blind placebo-controlled study of
6847 subjects treated with bazedoxifene or placebo, proved a
significant relative risk reduction of new vertebral fractures in
the group treated with bazedoxifene versus placebo [152].
Clinical studies of bazedoxifene in combination with estrogens
(randomized, placebo-controlled, Phase III studies with
daily bazedoxifene combined with conjugate estrogens com-
pared with raloxifene or placebo) evidenced better increases
in lumbar BMD for this treatment regimen (range
1.15 – 2.61%) compared with placebo (-1.92%). In this trial
among women within 5 years from menopause, the mean
increase from baseline in lumbar spine BMD at 2 years was
significantly greater for all bazedoxifene/conjugate estrogen
doses (range 1.15 – 2.61%) compared with raloxifene (0.15%;
p < 0.05) [153,154].
4.1.2 Lasofoxifene
The PEARL [155] study, a Phase III RCT, compared 3 years of
lasofoxifene 0.25 or 0.5 mg/daily versus placebo demonstrat-
ing that it improves significantly lumbar spine and femoral
neck BMD and reduces the risk of vertebral fractures by 31
and 42% (p < 0.002), respectively.
4.1.3 Arzoxifene
The FOUNDATION study, a Phase III, 2 years, randomized,
placebo-controlled trial including 331 postmenopausal
women with normal to low bone mass, evaluated the effects
of arzoxifene 20 mg/day on BMD. BMD resulted significantly
increased in the arzoxifene group both at the lumbar spine
(1.63%; p < 0.001) and at the total hip (1.08%; p < 0.001)
versus a significant decrease in BMD at the same sites in
the placebo group. Between groups, BMD comparisons
showed significant increases in the arzoxifene group at all
time points when compared with placebo. Moreover, in the
arzoxifene group, biochemical markers of bone metabolism
resulted significantly decreased versus placebo at each visit
(p < 0.001) [156].
4.1.4 Toremifene
Toremifene is a second generation SERM that is currently in
clinical development for the prevention and treatment of
osteoporosis in men receiving ADT for hormone sensitive
prostate cancer. Smith et al. have recently published an interim
analysis of 197 subjects of a multi-center, Phase III fracture
prevention study of 1392 men with prostate cancer receiving
ADT. They were randomized to receive either toremifene
80 mg/day or placebo. The group treated with toremifene had
significant increase in BMD at each skeletal site compared
with placebo, after 1 year of treatment. Between group
differences in BMD from baseline to month 12 were 2,
Table 5. Emerging drugs for the treatment of cancer treatment induced bone loss.
Compound Company Indication Stage of development Mechanism of action
Denosumab Amgen Osteoporosis
cancer, bone
cancer, prostate
cancer, breast
Pre-registration
Phase III clinical trials
Specifically inhibits RANKL and
suppresses bone resorption
Balicatib Novartis Osteoporosis Discontinued Cathepsin K inhibitor
Odanacatib Merk & Co. Osteoporosis Phase III clinical trials Cathepsin K inhibitor
Arzoxifene Eli Lilly Osteoporosis,hormone
replacement therapy,
breast cancer
Phase III clinical trials Agonist/antagonist action on
estrogen receptor
Antibodies to sclerostin In development Interferes in the signaling cascade
leading to an increased number
of activated osteoblasts
Antibodies to Dkk-1 In development Interferes in the signaling cascade
leading to an increased number
of activated osteoblasts
SARMs In development SARMs
RANKL: Receptor activator of NF-kB ligand; SARM: Selective androgen receptor modulator.
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3% at lumbar spine, 2% at total hip and 1, 5% at femoral neck
(Table 4) [157].
4.2 Cathepsin K inhibitors
Two cathepsin K inhibitors, balicatib and odanacatib, are
tested in humans and shown to reduce markers of bone
resorption and increase bone mass. A multi-center, random-
ized, placebo-controlled dose-finding study including 675
postmenopausal women treated with balicatib 50 mg daily
has been conducted by Adami et al. Markers of bone resorp-
tion declined by > 55% and BMD increased by 4.46% at the
lumbar spine and by 2.25% at the total hip [158,159]. McClung
et al. conducted a randomized, controlled trial of 399 post-
menopausal women, which evaluated the effects of four oral
doses of odanacatib given weekly on BMD and bone markers.
It showed dose-dependent increases in spine and hip density
(+5.5 and +3.2%, respectively), and a significative decline
of urine N-telopeptide of type I collagen and bone
specific alkaline phosphatase (-52 and -13%, respectively)
compared with a much smaller decline in the placebo group
(-3%) [160].
4.3 Antibodies to sclerostin
Antibodies to sclerostin have shown to increase bone forma-
tion in osteopenic estrogen-deficient rats. A single subcuta-
neous dose of an antibody to sclerostin in postmenopausal
women resulted in an increase in N-terminal propeptide of
type I collagen levels of 60 – 100% at the 84th day of
treatment, no increase in serum C-telopeptides and a 6%
increase in lumbar spine BMD [161].
4.4 Antibodies to dikkopf 1
Dikkopf 1 (Dkk1) antibodies preventing binding of dikkopf-1
to lipoprotein-receptor-related protein 5/6 have shown to
increase bone mass, bone volume and bone formation in
rodents. Antibodies to dikkopf-1 could be used as anabolic
agents for the treatment of patients with low bone mass [162].
4.5 Fulvestrant
Fulvestrant is an antagonist of the ERwithout agonist effects. It
is a specific drug in the class of the antiestrogenic therapies. In
all, 14 postmenopausal women with locally advanced or met-
astatic breast cancer received fulvestrant (250 mg monthly
intramuscular) as their first-line endocrine therapy in an
open-label prospective clinical trial. In this study, they analyzed
themean percent changes of bone specific alkaline phosphatase,
N-terminal propeptide of procollagen type 1 and C-terminal
telopeptide at 0, 1, 6, 12 and 18 months. This study, by
evidencing the stability of bone turnover markers, suggested an
apparent lack of effects of fulvestrant on bone turnover [163].
4.6 Selective androgen receptor modulators
Selective androgen receptor modulators (SARMs) largely
remain in the discovery and development stage, with a number
of agents in preclinical development, and only a few drugs
completing Phase I or II clinical trials up to now. No SARM
has been approved yet for clinical use [156].
5. Current research goals
At present, the use of endocrine adjuvant therapies improves
survival outcomes in breast and prostate cancers. In this
population of patients, the increasing awareness of CTIBL,
particularly of the fragility fractures risk, and effective
strategies to manage these adverse effects are required to
maintain good quality of life (QoL). The evidences of efficacy
of lifestyle modifications and pharmaceutical interventions
proven to reduce the fracture risk in postmenopausal women
and aging men are not directly applicable in CTIBL. The
discovery of new molecular targets in the cellular mechanisms
regulating bone turnover (e.g., RANKL/RANK/OPG axis,
Wnt-B catenin signaling) drives the research of new classes of
drugs. In this way, being the molecular mechanisms of
imbalance between osteoclasts and osteoblasts activity
involved in bone loss common to different conditions, such
as osteoporosis, CTIBL or bone metastasis, it is reasonable
that drugs with innovative mechanisms of action (e.g., deno-
sumab) need to be tested in RCTs in many conditions
characterized by disturbance of bone turnover. Nevertheless,
the evidences of efficacy concerning specific end points, for
example, reduction of fracture risk, obtained in one disease,
could not be considered suitable for other diseases. In fact, rate
of bone loss, incidence and type of fractures are probably quite
different among distinct conditions and, therefore, the doses,
the schedules of administration, the duration of the effects and
the safety should be tested for the specific indications. For
example, in CTIBL there is evidence that BPs, the standard
treatment for fracture risk reduction in postmenopausal oste-
oporosis, can prevent and partially recover bone loss (given in
different doses than osteoporosis), while the reduction of
fracture risk is not yet proven. There are a number of ongoing
studies with both oral and i.v. BPs, mainly in CTIBL, which
have not yet generated data. These studies will provide
evidences for the optimal strategy for reducing bone loss
and perhaps the resulting fractures.
A further intriguing field of research in emerging therapies
for CTIBL is the exploration of the combined use as well as the
sequential use of drugs with different molecular and/or cellular
targets in bone (e.g., BPs and denosumab) searching an
additive effect or a more convenient schedule or a longer
lasting effect. Finally, an important research goal should be the
comparison of efficacy, safety profile and compliance among
drugs with proven efficacy to define the best choice and offer
the best chance of therapy for CTIBL.
6. Scientific rationale
The scientific rationale for the use of these compounds in the
setting of the CTIBL is based on the mechanisms of action of
these drugs and on their capability of reducing bone turnover.
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We, therefore, briefly analyze the single role of each drug in
bone metabolism.
6.1 Bisphosphonates
BPs are stable analogues of pyrophosphate in which the
oxygen atom linked to two phosphate groups is replaced by
a germinal central carbon atom. They bind avidly to hydroxy-
apatite bone mineral surfaces, especially within resorption
cavities. Subsequently, they are taken up by local osteoclasts,
primarily through endocytosis [164]. Nitrogen-containing BPs
inhibit the mevalonate pathway, the main target being farnesyl
diphosphate synthase. Inhibition of the mevalonate pathway
leads to a loss of important prenylated proteins which are
required for the survival of the cell, finally inducing osteoclasts
apoptosis. In addition, build up of proximal metabolites in the
mevalonate pathway may have positive effects on immune
function including the expansion of gd T cells [110,164-168].
6.2 Denosumab
Bone loss is mediated by osteoclasts, whose formation, func-
tion and survival depend on the RANKL. RANKL binding to
its receptor RANK on preosteoclasts leads to the development
and activation of osteoclasts which maintain bone resorp-
tion [110-112]. Denosumab, a fully human mAb, specifically
inhibits RANKL and suppresses bone resorption.
6.3 Selective estrogen receptor modulators
SERMs are drugs with mixed agonist/antagonist action on
ERs in different tissues. In clinical trials, they have shown to
prevent bone loss and to lower serum cholesterol levels,
without stimulating the endometrium.
6.4 Cathepsin K inhibitors
Bone resorption by osteoclasts comprises both demineraliza-
tion of inorganic bone components and removal of organic
bone matrix. Demineralization requires acid secretion by
osteoclasts into resorption lacunae, whereas matrix degrada-
tion is accomplished by cysteine proteases including
cathepsin B, L, S and K [130]. Cathepsin K has high collagenase
activity and at the acidic pH present in the resorption lacunae
dissolves type I collagen. Elimination of cathepsin K in
osteoclasts results in inhibition of bone resorption.
6.5 Antibodies to sclerostin and Dkk1
The exploration of the mechanisms by which the formation of
bone is regulated during embryogenesis has clearly established
a role for members of the hedgehog family of proteins and
their receptors as well as for bone morphogenetic proteins and
their receptors [168-171]. Several marker genes of the osteoblast
lineage are now identified, and the picture that emerges is that
of a cascade of signaling pathways each of which activates the
expression of a few genes characteristic of the osteoblast
lineage as well as the expression of the ligand for the following
signaling cascade, ultimately leading to the expression of the
full set of genes characteristic of a mature, bone matrix
secreting osteoblast [172]. Antibodies to sclerostin and to
Dkk1 interfere in one of the numerous key points of this
signaling cascade leading to an increased number of activated
osteoblasts and, therefore, to an increase of the entire bone
mass. This effect is the base of a strong rationale for their use in
conditions of bone loss as PMO, male and glucocorticoid
osteoporosis. However, in cancer patients, the key roles of
osteoblasts in the bone homing of cancer cells and in the
creation/mainteinance of premetastatic niche raise some
concerns on their use in this setting of patients.
6.6 Fulvestrant
Fulvestrant is a new ER antagonist with no estrogen agonist
effect and has a novel mode of action. It binds, blocks and
increases degradation of ER protein leading to an inhibition of
estrogen signaling through the ER. It was recently approved
for the treatment of hormone receptor positive (HR+) met-
astatic breast cancer in postmenopausal women with disease
progression after antiestrogen therapy [173]. Fluvestrant seems
to reduce the trabecular bone loss in animal models after
ovariectomy [174]. However, the results of a small clinical pilot
study show a modest effect on bone resorption, lower than
expected [163].
7. Potential development issues
Prevention of CTIBL has become an important issue and
many BPs and denosumab are investigated in clinical trials
evaluating their effects on bone loss in this setting. Recent
guidelines and recommendations on management of
CTIBL [71-73] suggest the use of bone-targeted treatments
(mainly BPs) in patients with breast or prostate cancer at
very conservative BMD levels (for a T-score ranging between
-1 and -2) or in presence of other BMD-independent fracture
risk factors, regardless of BMD. This preventive approach is
based on the evidences of a better preservation of BMD if BPs
are started in the early stage of bone loss rather than delayed
after fractures or after significant bone loss has occured [27].
The potentially greater benefits of this approach on fracture
risk in CTIBL are based on the likely rationale that better
BMD (a surrogate end point of efficacy) probably corresponds
to a better bone quality and to a low risk of fracture. Only
recently, the preliminary evidences of the beneficial effects
of zoledronic acid in preventing not only bone loss but
more intriguingly the development of skeletal and non-
skeletal metastasis may suggest more specific indications
for the clinical use of BPs and potentially of other inhibitors
of bone turnover in the cancer setting. The goal of the
therapeutic approach will shift from bone mass preservation
to prevention of metastasis (skeletal and possibly nonskeletal).
Bone is not only the most frequent site of metastasis for
breast and prostate cancers, but as a great number of pre-
clinical data indicate, bone marrow microenvironment acts
as a niche for dormant cancer cells attracted through the
release of bone-derived cytokines and growth factors, till their
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development in bone metastasis or dissemination to extra-
osseus sites. Potent amino-BPs, as zoledronic acid, alone or in
combination with chemotherapy, could have a direct or
indirect antineoplastic effect, influencing bone microenviron-
ment and the survival of dormant cancer cells. Zoledronic acid
in two pilot studies significantly reduced at 1 year the number
of marrow disseminated tumor cells after adjuvant chemo-
therapy suggesting an antitumor effect within the bone
microenvironment [175-177]. Recenly, in the ABCSG-12 study,
the administration of zoledronic acid 4 mg every 6 months
primarily to prevent endocrine adjuvant bone loss was asso-
ciated with 35% improvement in disease free survival (DFS)
with a significant reduction of nonskeletal metastasis and
locoregional recurrence rate, too [178]. Similar improvements
in DFS have been presented from Z-FAST/ZO-FAST studies
and the results of ongoing trials using zoledonic acid, clo-
dronate and ibandronate with DFS and bone metastasis
free survival as primary end points (AZUR, SWOG,
GAIN, SUCCESS) are expected in the next year [179]. Other
developing drugs, that is, denosumab, interfering with bone
turnover and modulating bone microenvironment could
potentially be effective in the adjuvant setting.
We can suppose that if the antitumoral effect and the
improving of DFS of BPs are confirmed, their adjuvant
role should overcome the effects on bone mass preservation
in endocrine adjuvant treated patients becoming the primary
indication, anyway assuring the bone-sparing effect.
8. Conclusions
The hormone deprivation therapy is the standard therapy in
prostate cancer and recently the AIs showed a clear superiority
compared to tamoxifene in hormonal adjuvant therapy of
early breast cancer. Both the treatments are associated with an
increasing bone loss and fracture risk. CTIBL does not seem to
be determined through different pathogenic and molecular
mechanisms from PMO or aging male osteoporosis, even if it
shows about twofold higher rate of bone loss and fracture. At
the present, there are no available drugs registered to treat or
prevent CTIBL. Potentially all antiresorptive drugs, mainly
BPs, registered for PMO or male osteoporosis could be used,
even if none have demonstrated fracture risk reduction in this
specific setting of patients. Among these, zoledronic acid 4 mg
every 6 months has the largest body of evidences in the
prevention of CTIBL. Emerging drugs in this setting with
antiresorptive activity include denosumab, a fully human mAb
that specifically inhibits RANKL, cathepsin K inhibitors,
antibodies to sclerostin and Dkk1 and SERMs, which selec-
tively modulate the activity of ERs. These drugs are in parallel
developed for PMO but the dose, the schedule, the antifrac-
ture efficacy and the safety profile in this setting could not be
directly bridged to CTIBL. There is the necessity, for the
oncology community, of agents with efficacy and safety
profile specifically proven for CTIBL. The development of
new drugs for the market will require not only a challenge
on the efficacy and safety profile, which should be superior
to BPs but also on economic profile, considering the avail-
ability now of inexpensive generic alendronate and in the
next few years of all generic BPs.
9. Expert opinion
In recent years, bone health is becoming a central issue in
cancer patients, mainly in breast and prostate cancers. The
bone is involved at many stages of the natural history of the
cancer disease. Soon after chemotherapy in premenopausal
women or during endocrine adjuvant therapy, the increase of
bone turnover induces a rapid bone loss (and probably a rapid
deterioration of bone quality) that in turn increases the risk of
fragility fracture. Bone is a preferred site involved in metastatic
disease, with pain, skeletal related events (SREs: pathological
fractures, hypercalcemia, spinal compression, radiotherapy,
surgery) and loss of QoL that deeply impact on survival.
Finally, there are increasing evidences that a high bone
turnover is associated with a bone marrow microenvironment
enriched of cytokines and growth factors that attract cancer
cells, thus, creating a pre-metastatic niche promoting the
survival of dormant cells with a subsequent dissemination
to extra-skeletal sites. In the last 10 years, the increasing
scientific advances in understanding the molecular mechanism
of bone turnover and the close molecular cross-talk among
cancer cells, osteoblasts, osteoclasts, osteocytes and bone
marrow cells have revealed an intriguing pathophysiologic
and clinical network among the apparently separate clinical
conditions that involve the skeletal in cancer patient. So, high
bone turnover induces bone loss and bone fragility, promotes
the homing of cancer cells in bone and the development of
metastasis, increases the risk of SRE and is associated with
poor survival. Finally, it is likely that a frail osteoporotic bone
is more prone to an SRE than a healthy one. On this basis, the
normalization of bone turnover, recovering the normal bal-
ance between osteoblasts and osteoclasts functions, seems to be
the key to interrupt this vicious cycle that globally affects many
aspects of bone heath in cancer patients.
Among the antiresorptive drugs, the most potent inhi-
bitors of bone turnover are the amino-BPs, and among
amino-BPs, zoledronic acid is by far the most potent. In
this category of drugs, it is unlikely that greater significant
benefit could come from developing additional agents. For
example, denosumab, with the limit of the lack of head to
head comparison among antiresorptive drugs in CTIBL and in
PMO, suppresses bone turnover at the same level (-90%) of
zoledronic acid and reduces the incidence of vertebral and
non-vertebral fracture of the same extent (-70 and -30%,
respectively) [113].
Although for all amino-BPs nowadays there are evidences of
reducing fracture risk in different types of osteoporosis and
across a wide range of risk classes, data on the reduction of
fracture risk are lacking in CTIBL and there is no therapy
approved for this condition. However, recently, expert panels
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recognizing the necessity to address accelerated bone loss in
these at-risk populations and taking into account the negative
impact of fractures on patient independence and QoL,
combining the large body of evidences on prevention of
CTIBL, mainly using zoledronic acid, recommend that all
patients treated with endocrine adjuvant therapy should be
evaluated for the risk of CTIBL and eventually treated with
BPs [72,73]. Recent analysis of the Z-FAST trial demonstrates
that zoledronic acid is cost-effective in the prevention of
fractures in women with early breast cancer treated with
AI, particularly when the treatment is started before bone
loss has occurred [180].
Despite the above evidences, some questions remains
undetermined: which patients may benefit mostly from
preventive BPs and what are the optimal dose and frequency
of administration. In parallel, preliminary evidences support
an exciting new field of utilization of zoledronic acid: the
possibility of preventing skeletal and nonskeletal metastases.
The adjuvant role will be confirmed through the several
ongoing trials which have event-free survival and DFS as
primary end points. These trials could also demonstrate
whether treatment with adjuvant BPs has a class effect
and whether it is specific of certain agents. Awaiting the
confirmation of the adjuvant role of zoledronic acid or other
BPs, at present the use of zoledronic acid in prevention of
CTIBL is useful because of the additional benefits that
overcome BMD, covering all the targets of bone health in
a cancer patient. In this landscape, the development of new
drugs in the bone health field, as denosumab, with good
evidences in preventing bone loss in CTIBL and also in
reducing SRE in metastatic bone diseases, should be evaluated
not only for their efficacy differences, convenient administra-
tion or cost, but for their ability to prevent skeletal and
nonskeletal metastases.
Clearly, although there may be little added benefits from
developing additional agents of the antiresorptive cate-
gory for this setting of patients, new drugs with different
mechanisms of action and differently targeted on bone
could offer the opportunity to explore new strategies such
as a combined use with the new end point of preventing
bone metastasis.
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